drugset / Trial / NCT06413082
Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment
RandomizedParallel-groupDouble-blindTreatment
Summary
Phase III interventional study to evaluate the different efficacy of Torasemide and Spironolactone in reducing systolic blood pressure in carriers and non-carriers of the different genotypic combinations for Lanosterol and Uromodulin
Timeline
- Start
- 2021-02-15
- Primary completion
- 2023-07-07
- Completion
- 2023-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Spironolactone | Small molecule | 50 mg | Oral |
| Subject | Torasemide | Unknown | 2.5 mg | — |